Day Financial Statements From 2010 to 2024

DAWN Stock  USD 13.72  0.38  2.85%   
Day One financial statements provide useful quarterly and yearly information to potential Day One Biopharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Day One financial statements helps investors assess Day One's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Day One's valuation are summarized below:
Profit Margin
(0.83)
Market Capitalization
1.4 B
Enterprise Value Revenue
8.1199
Revenue
102 M
Earnings Share
(0.97)
We have found one hundred twenty available fundamental signals for Day One Biopharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Day One's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 25th of November 2024, Market Cap is likely to grow to about 1.4 B. Also, Enterprise Value is likely to grow to about 1.3 B
Check Day One financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Day One's main balance sheet or income statement drivers, such as Net Interest Income of 5.7 M, Depreciation And Amortization of 34.2 K or Interest Expense of 5.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.53. Day financial statements analysis is a perfect complement when working with Day One Valuation or Volatility modules.
  
Check out the analysis of Day One Correlation against competitors.

Day One Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets239.3 M376 M104.9 M
Slightly volatile
Other Current Liabilities27.4 M26.1 M6.4 M
Slightly volatile
Total Current Liabilities31 M29.5 M7.2 M
Slightly volatile
Accounts Payable2.7 M2.6 M545.1 K
Slightly volatile
Cash147.7 M230.8 M71 M
Slightly volatile
Cash And Short Term Investments234.1 M366.3 M102.9 M
Slightly volatile
Common Stock Total EquityK6.3 K1.5 M
Slightly volatile
Common Stock Shares Outstanding72.8 M79.8 M64.1 M
Slightly volatile
Other Current Assets4.6 M8.9 M1.7 M
Slightly volatile
Total Liabilities29.1 M29.5 M33.6 M
Very volatile
Total Current Assets238.7 M375.3 M104.6 M
Slightly volatile
Capital Stock8.6 KK1.5 M
Slightly volatile
Net Working Capital225.7 M345.8 M98.6 M
Slightly volatile
Common Stock8.6 KK1.5 M
Slightly volatile
Short and Long Term Debt Total506.8 K408 K424.7 K
Pretty Stable
Current Deferred Revenue30.8 M29.3 M7.3 M
Slightly volatile
Non Currrent Assets Other263.7 K214 K152.8 K
Slightly volatile
Deferred Long Term Liabilities28.8 K32.4 K35.3 K
Slightly volatile
Short Term Debt613.8 K816 K321.7 K
Slightly volatile
Property Plant Equipment17.1 K18 K361.7 K
Slightly volatile
Capital Surpluse555.7 M692 M450.2 M
Slightly volatile
Non Current Liabilities Other492.7 K469.2 K104.1 K
Slightly volatile

Day One Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense5.7 M5.5 M2.4 M
Slightly volatile
Selling General Administrative79.3 M75.5 M17.3 M
Slightly volatile
Other Operating Expenses216.4 M206.1 M53.7 M
Slightly volatile
Research Development137 M130.5 M36.3 M
Slightly volatile
Total Operating Expenses216.4 M206.1 M53.7 M
Slightly volatile
Interest Income4.1 M4.3 M22.9 M
Slightly volatile
Cost Of Revenue348.7 K383 K211.1 K
Slightly volatile
Preferred Stock And Other Adjustments80 M90 M98 M
Slightly volatile
Selling And Marketing Expenses306.4 K344.7 K375.3 K
Slightly volatile

Day One Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings800 K900 K980 K
Slightly volatile
Stock Based Compensation41.3 M39.3 M8.2 M
Slightly volatile
Begin Period Cash Flow97.1 M85.3 M36.5 M
Slightly volatile
Other Cashflows From Financing Activities2.5 M2.6 M12.6 M
Slightly volatile
Depreciation313.1 K383 K208.7 K
Slightly volatile
Capital Expenditures2.5 M3.2 M985.2 K
Slightly volatile
Issuance Of Capital Stock149.5 M161.4 M73.2 M
Slightly volatile
Total Cash From Financing Activities151.3 M164 M74.5 M
Slightly volatile
End Period Cash Flow147.7 M230.8 M71 M
Slightly volatile
Change To Netincome20.8 M31.3 M13.1 M
Slightly volatile
Change To Liabilities9.4 M8.9 M2.2 M
Slightly volatile
Sale Purchase Of Stock1.2 M1.2 M22.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation13.558.41784.5831
Slightly volatile
Payables Turnover0.140.14870.7257
Pretty Stable
Cash Per Share2.494.59241.4679
Slightly volatile
Days Payables Outstanding1.3 K2.5 K822
Slightly volatile
Income Quality0.450.77730.3756
Slightly volatile
Net Debt To EBITDA1.831.1181.2251
Slightly volatile
Current Ratio22.712.717716.5091
Slightly volatile
Graham Number15.9715.21414.3537
Slightly volatile
Capex Per Share0.04720.04040.0156
Slightly volatile
Interest Debt Per Share0.00490.00510.0285
Slightly volatile
Debt To Assets8.0E-40.00118.0E-4
Slightly volatile
Days Of Payables Outstanding1.3 K2.5 K822
Slightly volatile
Ebt Per Ebit1.580.91681.2694
Pretty Stable
Effective Tax Rate0.08580.08090.1122
Slightly volatile
Quick Ratio22.712.717716.5091
Slightly volatile
Net Income Per E B T0.740.840.8709
Very volatile
Cash Ratio7.437.821114.0248
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.161.0221.0281
Slightly volatile
Debt Ratio8.0E-40.00118.0E-4
Slightly volatile

Day One Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.2 B1.4 B
Slightly volatile
Enterprise Value1.3 B934.3 M1.3 B
Slightly volatile

Day Fundamental Market Drivers

Cash And Short Term Investments366.3 M

Day Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Day One Financial Statements

Day One investors utilize fundamental indicators, such as revenue or net income, to predict how Day Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue29.3 M30.8 M
Cost Of Revenue383 K348.7 K

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving against Day Stock

  0.47MTEM Molecular TemplatesPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out the analysis of Day One Correlation against competitors.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.